- Trial Phase
- Phase 2
- Time to Market
- At least 3-5 years, assuming successful Phase 2, Phase 3, and regulatory filing
- Why 6/10
- The next hard catalyst is the 12-week Phase 2 topline data readout for ARCT-032 in Class I cystic fibrosis patients (enrollment began Q1 2026; ~20 patients; data likely H2 2026). This is a make-or-break readout for the asset after the disappointing 28-day interim data, and ARCT-032 is a major (but not only) pipeline driver at a ~$196M market-cap company, placing it at impactScore 6.
Watch for the 12-week Phase 2 data from ARCT-032, likely in late 2026 — this is the pivotal efficacy readout after the disappointing 28-day FEV1 results. The recent Thermo Fisher partnership ($40M in-kind manufacturing + $40M CRO services) de-risks Phase 3 costs but doesn't remove binary risk on the data. If lung function improves over 12 weeks, the stock could rerate significantly (analyst mean PT ~$19.89 vs ~$6.89); if not, the program may be in serious jeopardy.
Price Chart
Executive Summary
ARCT-032 is Arcturus Therapeutics' lead pipeline asset — an inhaled mRNA therapy for cystic fibrosis (CF) targeting Class I mutation patients who cannot use existing CFTR modulator drugs like Vertex's Trikafta. The drug has FDA Orphan Drug and Rare Pediatric Disease designations. Interim 28-day Phase 2 data (Oct 2025) showed safety but no meaningful improvement in lung function (FEV1), causing the stock to drop ~50-56%. However, CT imaging showed mucus plug reduction in 4/6 patients. A longer 12-week Phase 2 study began enrollment in Q1 2026 with ~20 patients, and the company just signed a strategic Phase 3 partnership with Thermo Fisher (July 2026). The stock trades at ~$6.89 (market cap ~$196M) with analyst consensus of 9 Buy/4 Hold and mean price target ~$19.89 — implying large upside if the 12-week data shows lung function improvement.
How It Works
ARCT-032 is an inhaled messenger RNA (mRNA) medicine. It delivers genetic instructions directly to lung cells via a nebulizer, telling them to produce a working copy of the CFTR protein — the protein that is defective or missing in cystic fibrosis. By restoring CFTR function in the lungs, the therapy aims to fix the underlying cause of CF lung disease rather than just treating symptoms. It uses Arcturus' LUNAR lipid nanoparticle platform to get the mRNA into lung cells.
Trial Status
A Phase 2 multiple-ascending dose study (NCT06747858) is underway. The 28-day cohorts (10mg and 15mg daily doses) showed safety and tolerability but no meaningful FEV1 improvement at 4 weeks, though 4/6 patients in the 10mg cohort had mucus plug reduction on CT scans. A 12-week open-label Phase 2 study in ~20 Class I CF patients began enrollment in Q1 2026 and was dosing beyond one month as of May 2026.
The Two-Sided Case
Upcoming Catalysts
- 12-week Phase 2 open-label study topline data (enrollment started Q1 2026; data likely H2 2026)
- Phase 3 design and regulatory alignment discussions with FDA (planned for 2026)
- Potential expansion into additional CF mutation classes beyond Class I
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Arcturus Therapeutics Holdings Inc. 8-K ARCT ·Originating report